R. Finn
Hepatology · 2006–2021
A researcher in the Science corpus: 19 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 188 citations into it
- Epidemiology — 108 citations into it
Whom R. Finn trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts R. Finn overall
Papers from R. Finn's perspective
Ordered by how strongly the researchers R. Finn trusts endorse each paper. Same corpus, a different order for every researcher.
- Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
- Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (Annals of Surgery)
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan (Liver Cancer)
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (International Journal of Cancer)
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (Cardiovascular and Interventional Radiology)
- A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria (Annals of Surgery)
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. (Gastroenterology)
- Management of hepatocellular carcinoma: An update (Hepatology)
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
- Non-Alcoholic Fatty Liver Disease and Hepatocellular Cancer: A Systematic Review (Clinical Gastroenterology and Hepatology)
Their papers
- Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. (2021) — 1,360 citations
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (2021) — 898 citations
- Immunotherapies for hepatocellular carcinoma (2021) — 1,513 citations
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (2020) — 5,608 citations
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020) — 879 citations
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. (2019) — 1,410 citations
- CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) (2019) — 616 citations
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) — 1,383 citations
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019) — 3,139 citations
- AASLD guidelines for the treatment of hepatocellular carcinoma (2018) — 3,751 citations
- Molecular therapies and precision medicine for hepatocellular carcinoma (2018) — 1,675 citations
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. (2018) — 2,061 citations
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018) — 1,983 citations
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) — 3,215 citations
- Treating cancer with selective CDK4/6 inhibitors (2016) — 1,014 citations
- Palbociclib and Letrozole in Advanced Breast Cancer. (2016) — 2,471 citations
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. (2015) — 1,577 citations
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro (2009) — 1,330 citations
- Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. (2006) — 953 citations